Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations

Hironori Satoh, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)

Abstract

Although standard schedule of gefitinib was the administration of 250 mg tablet every day, many patients need dose reduction because of toxicities. However, the efficacy of such low-dose gefitinib for patients with epidermal growth factor receptor-mutated non-small cell lung cancer has rarely been evaluated. Methods: A post hoc comparison of the efficacy (response rate and survival) in patients treated with gefitinib with or without any dose reduction in NEJ002 study was performed. Results: Among 114 patients treated with first-line gefitinib in NEJ002, 61 (54%) continued gefitinib without any dose reduction until their diseases progressed, and 53 (46%) reduced their dose of gefitinib because of some toxicities. There was no significant difference of patient characteristics between the two groups. The progression-free survival of low-dose group tended to be better than that of standard-dose group (median progression-free survival, 11.8 versus 9.9 months; p = 0.144), and the overall survival of low-dose group was also better than that of standard-dose group (median survival time, 32.7 versus 25.3 months; p = 0.049). Conclusions: The results suggest that low-dose gefitinib may be clinically not inferior to standard-dose gefitinib for non-small cell lung cancer with sensitive epidermal growth factor receptor mutations. Prospective study of low-dose gefitinib is warranted especially for frail patients who need less toxic treatment.

Original languageEnglish
Pages (from-to)1413-1417
Number of pages5
JournalJournal of Thoracic Oncology
Volume6
Issue number8
DOIs
Publication statusPublished - 2011 Aug

Keywords

  • EGFR mutation
  • Gefitinib
  • Low-dose
  • Post hoc analysis

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations'. Together they form a unique fingerprint.

Cite this